These five stocks from sectors that have underperformed since last fall now offer long-term growth and income investors some outstanding value with a much lower risk profile.
Taking profits on momentum growth and moving some capital to these safer value plays may be a very timely move. Here are four strong value plays that all pay significant dividends.
Merrill Lynch has released a list of 11 top stock picks for 2020 heading into the new year that fit within the themes for value, yields at a reasonable price and so on.
The top analyst upgrades, downgrades and initiations seen on Monday included AK Steel, CRISPR, Dell Technologies, DocuSign, Grubhub, NRG Energy, U.S. Steel, Vale, Wayfair and Zynga.
Wildfires have ripped through Southern California, Greece, and Brazil. A hurricane ravaged North and South Carolina. Massive flooding inundated southern India. Venice waters rose, flooding shops amid...
The included Achaogen, Apple, Athenahealth, Crocs, Finisar, Jabil, Michael Kors, Occidental Petroleum, Starbucks and Walt Disney.
This year marks the 54th annual meeting of the American Society of Clinical Oncology, the world’s largest clinical cancer conference.
The top analyst upgrades, downgrades and other research calls from Thursday include Apache, Apple, Berkshire Hathaway, eBay, GrubHub, Hess, Nike, Nucor and Wayfair.
Tronc has bought the New York Daily News, United Technologies bought Rockwell Collins, Elon Musk predicted what could start Word War III, and other important headlines.
Idera Pharmaceuticals is focused on cancer and rare diseases, and it could be a what traders refer to as a three-bagger or four-bagger, if two analysts who made key calls in recent days end up being...
Shares of Idera Pharmaceuticals sank on Thursday after the company announced that it intends to have a secondary offering.
Bluebird Bio, Idera Pharmaceuticals and others stood out from other biotech stock with incredible gains or losses over the course of the past week.
Idera Pharmaceuticals made a strong push in Monday’s session following the presentation of its clinical data over the weekend.
The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks in the group just are not carrying their weight.
Civeo has announced that due to the fall in oil prices it has cut its 2015 guidance and suspended its dividend.